Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (792)	8/28/2001 8:44:59 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 1834

FWIW:from the Briefing.com Short Stories(free) section: Neurocrine Biosci (NBIX) 38.20: UBS Warburg upgrades to STRONG BUY from BUY and raises price target to $50 from $46; company-specific and overall industry trends provide a favorable backdrop for NBIX as we enter the second half of this year; believes investors will be increasingly focused on the biotech sector as we move into the fall conference season; upgrade based on the following two near-term catalysts: 1) firm believes NBIX will release positive Phase II results for NBI-34060, its lead compound for insomnia, during late-September; and, 2) thinks NBIX will announce a marketing partner for 34060 in late 2001 or early 2002 that will help validate the drug's commercial potential. Jim